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Background/aim: The uptake of the ferric-acinetobactin complex into the periplasmic space relies on the baumannii acinetobactin
utilization (BauA) protein. BauA is composed of cork and the β-barrel domains. We constructed a recombinant protein from conserved
antigenic domains of cork and the β-barrel of BauA to evaluate their immunogenic role in an animal model.
Materials and methods: The selected bauA domains were amplified from a purified genome of Acinetobacter baumannii ATCC 19606.
The domains were then cloned into pET28a and the proteins expressed in E. coli BL21 (DE3) were purified using nickel nitrilotriacetic
acid chromatography. Mice and rabbits were immunized with an intraperitoneal injection of the recombinant BauA (rBauA).
Results: The highest immune response was achieved after the third booster injection while hyperimmunity was achieved after the
second booster injection in rabbits. Immunized mice challenged with live A. baumannii survived, whereas all unimmunized mice in the
control group died after 24 h. Mice injected with 109 colony forming units of A. baumannii preincubated with pure immune rabbit sera
survived. Bacterial cultures from mice spleen and liver specimens revealed the absence of bacterial growth in the immunized groups.
Conclusion: The rBauA could be used as a prophylactic agent and further tests should be carried out to see if it may be useful in a
clinical setting against A. baumannii infections.
Key words: Acinetobacter baumannii, baumannii acinetobactin utilization, siderophore, vaccine

1. Introduction
Acinetobacter baumannii is a gram-negative opportunistic
pathogen that causes nosocomial infections such
as pneumonia, urinary tract infection, bacteremia,
meningitis, and wound infection (1). The bacteria cause
illness mostly in patients hospitalized in an intensive
care unit (ICU) or with a compromised immune system
(2). Additionally, this bacterium is emerging as multi- or
pandrug-resistant, which makes treatment much more
difficult (3–5). Thus, the rate of mortality is relatively
high (6) and alternative therapeutic targets seem to be
necessary to combat the bacterium. Iron is an essential
micronutrient for all living organisms. All aerobic and
anaerobic bacteria, except for Lactobacillus and the
causative agent of Lyme disease, need iron for survival (7).
Iron, functioning as a cofactor, has a significant role in the
* Correspondence: rasooli@shahed.ac.ir
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key metabolic processes and pathogenesis of bacteria (8).
In mammals, free iron binds to carrier proteins such as
lactoferrin and transferrin (9), and thus the iron needed for
bacterial pathogenesis is restricted. This is considered to
be a protective mechanism against bacterial pathogenesis
(10–12). Bacteria have developed alternative mechanisms
for iron uptake to overcome this limitation. One of the
most important mechanisms is synthesis and secretion
of siderophores. Siderophores have a low molecular
weight and a high affinity to Fe(III) (13). Consequently,
iron-regulated outer membrane proteins (IROMPs) are
expressed on the bacterial surface to uptake the ferricsiderophore complex (14). For A. baumannii, iron uptake
is one of the processes known to play a key role in infection
and establishment in the host (15). Acinetobactin, a
catecholate siderophore composed of equimolar quantities
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of 2,3-dihydroxybenzoic acid, L-threonine, and N-hydroxy
histamine, is secreted for iron chelating in A. baumannii
(16). Uptake of the ferric-acinetobactin complex into the
periplasmic space relies on the baumannii acinetobactin
utilization (BauA) protein (17). BauA is the most important
outer membrane protein in pathogenic Acinetobacter
species and especially Acinetobacter baumannii, belonging
to the TonB-dependent transporter protein family, and it
is expressed under iron-limited conditions (18,19). Similar
to other gram-negative bacterial siderophore-Fe receptors,
BauA is composed of 2 domains, the cork and the β-barrel.
The latter is composed of 22 transmembrane antiparallel
β-strands. The cork is the smallest domain of the protein
and is composed of 4 antiparallel hydrophobic β-strands
at the N-terminal. The cork domain functions as a plug
that keeps the barrel domain channel closed in the absence
of the ferric-acinetobactin complex (18). This study
encompasses construction of a recombinant protein from
conserved antigenic domains of cork and the β-barrel to
evaluate their immunogenic role in a mice model.
2. Materials and methods
2.1. Selection of antigen
The conserved antigenic regions of BauA were chosen
from our earlier report (18). Epitope mapping studies
resulted in the selection of the plug region and the β-barrel
domain of the protein. The selected recombinant BauA
used in this study was constructed from the coding regions
of the cork domain to loop 9 end of the bauA gene of A.
baumannii ATCC 19606.
2.2. Gene cloning, protein expression, and purification
Two specific primers (forward: 5′-GGATCCATGGATAA
TTCAACAAAAACTCTA GAAC-3′, reverse: 5’-AGATC
CCACTCTGCTCCAA-3′) were designed for the isolation
and amplification of the selected bauA domains from
the purified genome of A. baumannii ATCC 19606. The
selected DNA segment was then cloned into the pET28a
(+) (Novagen Company, USA) expression vector by
BamHI and SalI (Fermentas, Denmark) as 5’ and 3’
restriction enzymes, respectively. The selected bauA gene
contains an NdeI restriction site on nucleotide 894. The
cloning process was analyzed by plasmid digestion and
restriction mapping with an NdeI restriction enzyme.
Recombinant constructs were transferred into E. coli
BL21 (DE3). Transformed bacteria were cultured in
Luria-Bertani (LB) medium containing of 70 µg/mL of
kanamycin. A single bacterial colony was cultured in LB
medium and incubated until the optical density at 620
nm reached 0.7. The expression was induced with 1 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) and the
culture was incubated at 37 °C at 250 rpm for 4 h. Cells
were collected by centrifugation at 10,000 × g for 10 min.
The pellet was resuspended in lysis buffer (100 mM H2PO4,

10 mM Tris base, 8 M urea, pH 8). Cells were disrupted
by sonication and the supernatant was discarded after
centrifugation at 12,000 × g at 4 °C for 20 min. Expression
was analyzed by 9% SDS-PAGE. The recombinant protein
BauA was purified using nickel nitrilotriacetic acid (NiNTA) chromatography with gradient reduction in pH.
Purification was examined by 9% SDS-PAGE. Urea was
removed by dialysis in phosphate-buffered saline (PBS)
and reduced concentrations of urea. Protein concentration
was calculated by the Bradford method (20).
2.3. Animal husbandry
BALB/c male mice, of 4–6 weeks old and weighing 16–22
g, and New Zealand White male rabbits were procured
from the Razi Institute, Tehran, Iran. Mice were housed
under standard, clean, and well-aerated conditions in the
animal care facility at Shahed University. Research was
conducted in compliance with the Animal Welfare Act
and regulations related to experiments involving animals.
The principles stated in the Guide for the Care and Use of
Laboratory Animals were followed (21). The animal care
protocol was ethically approved by Shahed University.
2.4. Animal immunization
Fifteen mice were immunized with an intraperitoneal
(IP) injection of 10 µg of the recombinant BauA (rBauA)
emulsiﬁed in an equal volume of complete Freund’s
adjuvant. The subsequent 3 booster doses were given
with 10 µg of rBauA emulsiﬁed in incomplete Freund’s
adjuvant. The control mice received an equal amount of
adjuvant alone. The same procedure was applied to the
rabbits with 100 µg of rBauA.
2.5. Determination of antibody titers
The immune response in mice and rabbits was analyzed
by indirect enzyme-linked immunosorbent assay
(ELISA). Briefly, 5 µg of rBauA was coated with 100 µL
of bicarbonate/carbonate coating buffer (100 mM, pH 9.6)
in a 96-well ELISA microplate. The plate was incubated
at 4 °C for 16 h. Each well was washed with 200 µL of
PBS-T (PBS buffer 1X + 0.05% Tween 20). Serial dilutions
of sera were prepared, 100 µL of which was added to the
designated wells, and the plate was incubated for 2 h
at 37 °C. The wells were washed 3 times with 200 µL of
PBS-T. Then 100 µL of antimouse or antirabbit antibody
conjugated with horseradish peroxidase (HRP) was added
to the wells treated with mouse or rabbit sera, respectively.
After 1 h of incubation at 37 °C, the wells were washed as
before and each well received 100 µL of TMB substrate.
The immunoreaction was stopped after 15 min with the
addition of 100 µL of 3 N H2SO4. The absorbance was read
at 450 nm.
2.6. Western blotting
Western blotting with anti-His-tag antibodies (QIAGEN,
USA) was carried out to confirm protein expression.
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The rBauA was transferred from 12% SDS-PAGE gel to
nitrocellulose paper using a Bio-Rad Mini-Protean Tetra
System run for 60 min at 75 V. The nitrocellulose paper
was stained with Ponceau S and destained with PBS (pH
7.2). Nitrocellulose paper was incubated with blocking
buffer (5% skimmed milk in PBS-T [PBS + 0/05% Tween
20]) overnight at 4 °C. After washing 4 times with washing
buffer (PBS-T) on the shaker for 5–10 min each time, antiHis-tag antibodies were added to a final concentration
of 1/1000 and incubated for 1 h in 37 °C. Washing was
repeated as described above. The substrate buffer (50 mM
Tris-HCl (pH 7.2), 0.6 mg/mL DAB, and 1 µL/mL H2O2)
was added and the reaction was stopped with PBS.
2.7. Chrome azurol S assay
The bacterial ability to grow in the presence of 100
µM iron chelator 2,2′-dipyridyl (DIP) (Sigma-Aldrich,
Munich, Germany) was determined by using tryptone
soy broth supplemented with 1% NaCl as a basal medium.
This compound had no effect on the pH of the medium
or on the growth rate of the bacterium (22). To evaluate
the capacity of siderophore production by A. baumannii
ATCC 19606, a universal chemical assay on chrome
azurol S (CAS) agar plates was used (23). The bacterium
was cultured on tryptone soy agar medium supplemented
with 1% NaCl for 48 h at 37 °C. The assay was performed
by spotting 10 µL of bacterial culture onto CAS agar. The
siderophores produced by A. baumannii ATCC 19606 on
plates were detected by the appearance of an orange halo
around microbial colonies after 72 h of incubation up to 7
days postinoculation.
2.8. Determination of lethal dose (LD50)
The lethal dose (LD50) was calculated in mice by IP
injection of A. baumannii at doses ranging from 104 to 109
CFU into 6 groups of 5 BALB/c mice. For challenge assay,
the immunized mice were randomly divided into 3 groups
of 5 animals. Mice in groups 1, 2, and 3 were challenged
with IP injection of 108, 109, and 1010 CFU of A. baumannii
ATCC 19606, respectively.
2.9. Neutralization test
For neutralization assay (24), 4 groups of healthy mice
were taken under study. Groups 1 and 2 were further
subdivided into 5 groups of 5 animals. A. baumannii at
109 and 1010 CFU concentrations was mixed with 200 µL
of immune rabbit serum at pure, 1/250, 1/500, 1/1000,
and 1/5000 ratios and incubated for 30 min at 37 °C. The
mixtures were then injected intraperitoneally to the mice
groups. To analyze the specificity of immune response
against BauA protein, 105 CFU of Staphylococcus aureus
with LD50 of 104 was mixed with 200 µL of pure immune
rabbit serum and injected intraperitoneally into the mice
in group 3. Group 4 received 200 µL of rabbit serum only,
to serve as the control. The animals were monitored for
mortality for 1 week.
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2.10. Monitoring establishment of A. baumannii
infection
The immunized and unimmunized mice inoculated
intraperitoneally with 109 and 1010 CFU of live A.
baumannii were sacrificed and the liver and spleen
were removed aseptically to test for the presence of A.
baumannii. Each organ was homogenized separately and
0.1 g of each homogenate was suspended in 1 mL of PBS.
Then 100 µL of each suspension was cultured in LB agar.
The bacterial colonies were counted (25) and suspensions
were prepared to verify the presence of A. baumannii
through routine laboratory methods. Livers and spleens
from healthy animals served as the control.
2.11. Statistical analysis
The data are expressed as mean ± standard deviation (SD).
P-values were calculated by Student’s t-test to determine
the significance of differences in the experimental groups.
P < 0.05 was considered significant.
3. Results
3.1. Cloning
PCR amplification of the rBauA gene resulted in a 1800bp fragment. The fragment was purified and cloned into
a pET28a (+) vector. Cloning was confirmed by digestion
with the cloning restriction enzymes and restriction
mapping with NdeI. There is an NdeI restriction site both
on the pET28a (+) vector at nucleotide 239 and on bauA
at nucleotide 894. Restriction mapping resulted in a 934bp fragment, confirming the cloning of the selected bauA
gene.
3.2. Protein expression and purification
Induction with 1 mM IPTG brought about a high
expression of rBauA. Inclusion bodies were dissolved in
a lysis buffer containing 8 M urea. SDS-PAGE analysis
revealed a thick protein band of 68 kDa. Ni-NTA
chromatography purification resulted in a single band of
68 kDa designated as rBauA (Figure 1). The expression was
confirmed with western blotting using HRP-conjugated
anti-His antibodies (Figure 2).
3.3. Animal immunization, challenge, and neutralization
test
The highest immune response in BALB/c mice was achieved
after the third booster injection while hyperimmunity
was achieved after the second booster injection in rabbits
(Figure 3). The difference in antibody titer between the
first and second doses of immunization was statistically
significant (P < 0.003). The rise in antibody titer after the
third immunization was also significant (P < 0.004), while
there was no statistically significant rise after third dose.
3.4. Determination of lethal dose (LD50)
The LD50 for A. baumannii was determined as 108 CFU for
BALB/c mice. Immunized mice were challenged with live
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Figure 1. SDS-PAGE analysis of recombinant BauA protein. Lane 1: Uninduced control, Lane 2: expression of rBauA protein induced with
1 mM IPTG, Lane 3: standard protein molecular weight marker, Lane 4: purification of rBauA protein with QIAGEN buffer E, Lanes 5 and
6: column effluent after washing with QIAGEN buffers D and C respectively, Lane 7: column effluent after loading induced lysed cells.

Figure 2. Western blot analysis of rBauA protein. Lane 1: 68-kDa band refers to the purified rBauA protein; Lane M: Protein molecular
weight marker.
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Figure 3. Immunization of mice and rabbit with rBauA.

A. baumannii. Mice in groups 1, 2, and 3 survived, whereas
all unimmunized mice in the control group died after 24 h.
3.5. Neutralization test
Mice injected with 109 CFU of A. baumannii preincubated
with pure immune rabbit sera survived, while all higher
sera dilutions did not impart protection.
3.6. Monitoring establishment of A. baumannii infection
Bacterial cultures from mice spleen and liver specimens
revealed an absence of bacterial growth in the immunized
groups. In the unimmunized mice, 6 × 104/g and 4 × 104/g
bacteria were detected in the spleen and liver, respectively.
4. Discussion
A. baumannii is one of the fastest growing nosocomial
infection causes worldwide. Generally, in addition to
elderly and premature infants, the population under risk
consists of immune-deficient people, patients hospitalized
in an ICU, and patients who underwent surgical procedure
or trauma (26). A. baumannii is a known cause of hospitalacquired infection and the spread of multidrug-resistant
strains of the bacteria in hospitals leads to complexity in
antibiotic mediated treatment (4). Thus, research toward
discovery of new therapeutic methods that could assist
or replace antibiotic treatment is imperative. Comparison
between A. baumannii (susceptible and multidrugresistant) and environmental Acinetobacter baylyi
revealed that multiple factors such as pilus biogenesis,
metabolism, quorum sensing, secretive system type
4, and iron acquisition are among the key virulence
factors of A. baumannii (15). There has been increasing
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success in the antibody-mediated treatment of various
bacterial infections (27–29). Recently, researchers have
successfully used the siderophore receptor as one of the
most conserved interspecies antigens to produce vaccines
against meningococci, E. coli O157, and avian salmonella
infections (30–32). In the case of A. baumannii, other
surface antigens, such as biofilm associated protein, have
been evaluated as potential vaccine candidates (33). The
protective efficiency of A. baumannii siderophore receptor
protein (BauA), a conserved antigen among the species
that is a key protein in the iron intake process, against
bacterial infection was evaluated in an animal model (17).
Bioinformatics studies of our earlier reports showed that
this protein exists in all pathogenic A. baumannii strains
(18). The CAS assay results showed that this bacterium
absorbs iron from the environment and in iron-deficient
media secretes siderophores for iron absorptions. Similar
studies in BALB/c mice indicates that monoclonal
antibodies against IROMPs of A. baumannii have in vitro
bactericidal and opsonization effects and can inhibit iron
absorption and siderophore function in the bacterium
(34). In this study, instead of cloning all the proteins
expressed in the iron-deficient state, a recombinant version
of BauA protein was used. Moreover, with the assistance
of bioinformatics studies, conserved antigenic regions
were selected to ensure a protective immune response and
less side-reaction with the use of smaller proteins (18).
The ELISA results showed maximum antibody titer after
the third booster injection in mice. Neutralization assay
using rabbit serum against a bacterial load of 109 showed
successful inhibition of the infection with only equal
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volumes of pure serum. This probably shows the important
role of the opsonization effect of these antibodies in the
eradication of infection, because all immunized mice could
tolerate higher doses of bacterial challenge with signs of
neither infection nor colonization in internal organs. The
immunized mice could tolerate 100 times the normal LD50
dose. The spleen and liver microbiology of the immunized
mice revealed an absence of A. baumannii, confirming the
efficacy of the antibodies produced against rBauA. rBauA
was able to create rapid induction of humoral immunity
within 10 days after the first injection dose in rabbits,
which is an important factor in immunogenicity. The rapid
growth of multidrug-resistant strains of A. baumannii
require significant attention to be given to nonantibiotic
methods of treatment. As shown in our experiments, the
mice injected with A. baumannii preincubated with sera

from rabbits immunized with rBauA survived. Production
of vaccines that could effectively prevent bacterial
colonization could significantly aid diagnostic and
therapeutic aspects of nosocomial infections caused by
this bacterium. The results support the efficacy of rBauA
as a prophylactic agent against A. baumannii infections.
The mice model presents an advantage in testing
immunization with recombinant proteins, especially in A.
baumannii infections where the animals are easily infected
with the bacterium. The lack of clinical experiments on
humans may be regarded as a shortcoming of the study.
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